Search

Your search keyword '"Macro, M."' showing total 316 results
Start Over Author "Macro, M."
316 results on '"Macro, M."'

3. Teclistamab for relapsed refractory multiple myeloma patients on dialysis.

Author

Lebreton, P., Lachenal, F., Bouillie, S., Pica, G. M., Aftisse, H., Pascal, L., Montes, L., Macro, M., Johnson, N., Harel, S., Fernandez, M., De Renzis, B., Lioure, B., Lazareth, A., Javelot, M., Louni, C., Huart, A., and Perrot, A.

Subjects
CYTOKINE release syndrome, COVID-19, BISPECIFIC antibodies, GLOMERULAR filtration rate, EXTRAMEDULLARY diseases
Abstract

The article discusses the use of teclistamab, a humanized immunoglobulin bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) who are on dialysis. The study, conducted in France, included 15 dialysis-dependent RRMM patients who were treated with teclistamab. The results showed promising responses in most patients, with manageable side effects such as cytokine release syndrome and infections. The study suggests that teclistamab monotherapy could be a feasible and safe option for patients with dialysis-dependent RRMM who are typically excluded from clinical trials. [Extracted from the article]

Published
2024
Full Text
View/download PDF

4. Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.

Author

Carras, S., primary, Torroja, A., additional, Emadali, A., additional, Daguindau, N., additional, Tempescul, A., additional, Macro, M., additional, Moreau, A., additional, Tchernonog, E., additional, Houot, R., additional, Schmitt, A., additional, Dartigeas, C., additional, Dupuis, J., additional, Jardin, F., additional, Banos, A., additional, Corm, S., additional, Barbieux, S., additional, Zerazhi, H., additional, Arkam, Y., additional, Fouillet, L., additional, Fontan, J., additional, Vilque, J., additional, Moles, M., additional, Sarkozy, C., additional, Morineau, N., additional, Joly, B., additional, Voillat, L., additional, Alexis, M., additional, Fornecker, L. M., additional, Garidi, R., additional, Amorim, S., additional, Bouabdallah, K., additional, Dorvaux, V., additional, Chabrot, C., additional, Feugier, P., additional, Damaj, G., additional, Fleury, J., additional, Delwail, V., additional, Ysebaert, L., additional, Burroni, B., additional, Callanan, M., additional, Legouill, S., additional, and Gressin, R., additional

Published
2023
Full Text
View/download PDF

5. P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY

Author

Weisel, K., primary, Kumar, S., additional, Moreau, P., additional, Bahlis, N., additional, Facon, T., additional, Plesner, T., additional, Orlowski, R., additional, Basu, S., additional, Nahi, H., additional, Hulin, C., additional, Quach, H., additional, Goldschmidt, H., additional, O’Dwyer, M., additional, Perrot, A., additional, Venner, C., additional, Raje, N., additional, Tiab1, M., additional, Macro, M., additional, Frenzel, L., additional, Leleu, X., additional, Pei, H., additional, Krevvata, M, additional, Carson, R, additional, Borgsten, F., additional, and Usmani, S., additional

Published
2023
Full Text
View/download PDF

6. B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK

Author

Roussel, M., primary, Pirotte, M., additional, Gounot, R., additional, Queru, K., additional, Rizzo, O., additional, Royer, B., additional, Harel, S., additional, Desport, E., additional, Huart, A., additional, Niault, M., additional, Karlin, L., additional, Decaux, O., additional, Chalopin, T., additional, Carpentier, B., additional, Macro, M., additional, Vignon, M., additional, Chalayer, E., additional, Stoppa, AM., additional, Bridoux, F., additional, and Jaccard, A., additional

Published
2023
Full Text
View/download PDF

7. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma

Author

Fouquet, G., Pegourie, B., Macro, M., Petillon, M.O., Karlin, L., Caillot, D., Roussel, M., Arnulf, B., Mathiot, C., Marit, G., Kolb, B., Stoppa, A.M., Brechiniac, S., Richez, V., Rodon, P., Banos, A., Wetterwald, M., Garderet, L., Royer, B., Hulin, C., Benbouker, L., Decaux, O., Escoffre-Barbe, M., Fermand, J.P., Attal, M., Avet-Loiseau, H., Moreau, P., Facon, T., and Leleu, X.

Published
2016
Full Text
View/download PDF

10. P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT

Author

Decaux, O., primary, Hulin, C., additional, Perrot, A., additional, Macro, M., additional, Frenzel, L., additional, Diels, J., additional, Perualila, N. J., additional, Ghilotti, F., additional, Haefliger, B., additional, Goldsztajn, E., additional, Vernet, S., additional, Thevenon, J., additional, Willaime, M., additional, Texier, N., additional, Schecter, J. M., additional, Madduri, D., additional, Jackson, C., additional, Valluri, S., additional, and Moreau, P., additional

Published
2022
Full Text
View/download PDF

11. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE

Author

Schavgoulidze, A., primary, Perrot, A., additional, Cazaubiel, T., additional, Leleu, X., additional, Manier, S., additional, Buisson, L., additional, Maheo, S., additional, Do Souto Ferreira, L., additional, Lannes, R., additional, Pavageau, L., additional, Hulin, C., additional, Marolleau, J.-P., additional, Voillat, L., additional, Belhadj, K., additional, Divoux, M., additional, Slama, B., additional, Brechignac, S., additional, Macro, M., additional, Stoppa, A.-M., additional, Sanhes, L., additional, Orsini-Piocelle, F., additional, Fontan, J., additional, Chretien, M.-L., additional, Demarquette, H., additional, Mohty, M., additional, Avet-Loiseau, H., additional, and Corre, J., additional

Published
2022
Full Text
View/download PDF

12. P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY)

Author

Lee, H. C., primary, Ramasamy, K., additional, Macro, M., additional, Davies, F. E., additional, Abonour, R., additional, van Rhee, F., additional, Hungria, V. T., additional, Puig, N., additional, Ren, K., additional, Silar, J., additional, Enwemadu, V., additional, Cherepanov, D., additional, Stull, D. M., additional, and Leleu, X., additional

Published
2022
Full Text
View/download PDF

13. P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER

Author

Macro, M., primary, Decaux, O., additional, Perrot, A., additional, Royer, B., additional, Chretien, M., additional, Belhadj, K., additional, Mohty, M., additional, Frenzel, L., additional, Leleu, X., additional, Dib, M., additional, Allangba, O., additional, Zunic, P., additional, Botoc, I., additional, Malfuson, J., additional, Moreau, P., additional, Garlantazec, R., additional, Texier, N., additional, Germain, R., additional, Deal, C., additional, and Hulin, C., additional

Published
2022
Full Text
View/download PDF

14. P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).

Author

Macro, M., primary, Touzeau, C., additional, Mariette, C., additional, Manier, S., additional, Brechignac, S., additional, Vincent, L., additional, Hebraud, B., additional, Decaux, O., additional, Schulmann, S., additional, Lenoir, C., additional, Godmer, P., additional, Farge, A., additional, Peyro Saint Paul, L., additional, Parienti, J.-J., additional, and Leleu, X., additional

Published
2022
Full Text
View/download PDF

15. P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01

Author

Bobin, A., primary, Manier, S., additional, De Keizer, J., additional, Karlin, L., additional, Perrot, A., additional, Hulin, C., additional, Caillot, D., additional, Mariette, C., additional, Lenain, P., additional, Richez, V., additional, Tiab, M., additional, Touzeau, C., additional, Jaccard, A., additional, Decaux, O., additional, Araujo, C., additional, Belhadj, K., additional, Benboubker, L., additional, Déal, C., additional, Macro, M., additional, Vincent, L., additional, Arnulf, B., additional, Bareau, B., additional, Braun, T., additional, Calmettes, C., additional, mamoun, D., additional, Zerazhi, H., additional, Demarquette, H., additional, Feugier, P., additional, Fohrer-sonntag, C., additional, Godet, S., additional, Petillon, M.-O., additional, Avet-Loiseau, H., additional, and Leleu, X., additional

Published
2022
Full Text
View/download PDF

16. P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY

Author

Hulin, C., primary, Macro, M., additional, Perrot, A., additional, Royer, B., additional, Caillot, D., additional, Belhadj, K., additional, Frenzel, L., additional, Benramdane, R., additional, Demarquette, H., additional, Bareau, B., additional, Darre, S., additional, Calmettes, C., additional, Le Calloch, R., additional, Bouketouche, M., additional, Laribi, K., additional, Texier, N., additional, Willaime, M., additional, Deal, C., additional, Moreau, P., additional, and Decaux, O., additional

Published
2022
Full Text
View/download PDF

17. S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04

Author

Touzeau, C., primary, Perrrot, A., additional, Hulin, C., additional, Manier, S., additional, Macro, M., additional, Chretien, M.-L., additional, Karlin, L., additional, Decaux, O., additional, Jacquet, C., additional, Tiab, M., additional, Leleu, X., additional, Planchce, L., additional, Avet-Loiseau, H., additional, and Moreau, P., additional

Published
2022
Full Text
View/download PDF

18. P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

Author

Facon, T., primary, Kumar, S. K., additional, Plesner, T., additional, Moreau, P., additional, Bahlis, N., additional, Goldschmidt, H., additional, O’Dwyer, M., additional, Perrot, A., additional, Venner, C. P., additional, Weisel, K., additional, Mace, J. R., additional, Raje, N., additional, Tiab, M., additional, Macro, M., additional, Frenzel, L., additional, Leleu, X., additional, Pei, H., additional, Borgsten, F., additional, and Usmani, S. Z., additional

Published
2022
Full Text
View/download PDF

19. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Author

Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, and Avet-Loiseau, H

Published
2014
Full Text
View/download PDF

21. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Author

Facon, T, Kumar, SK, Plesner, T, Orlowski, RZ, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M, Perrot, A, Venner, CP, Weisel, K, Mace, JR, Raje, N, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Wang, J, Van Rampelbergh, R, Uhlar, CM, Tromp, B, Delioukina, M, Vermeulen, J, Usmani, SZ, Facon, T, Kumar, SK, Plesner, T, Orlowski, RZ, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M, Perrot, A, Venner, CP, Weisel, K, Mace, JR, Raje, N, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Wang, J, Van Rampelbergh, R, Uhlar, CM, Tromp, B, Delioukina, M, Vermeulen, J, and Usmani, SZ

Abstract

BACKGROUND: In the primary analysis of the phase 3 MAIA trial (median follow-up 28·0 months), a significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in transplantation-ineligible patients with newly diagnosed multiple myeloma. Here, we report the updated efficacy and safety results from a prespecified interim analysis for overall survival. METHODS: MAIA is an ongoing, multicentre, randomised, open-label, phase 3 trial that enrolled patients at 176 hospitals in 14 countries across North America, Europe, the Middle East, and the Asia-Pacific region. Eligible patients were aged 18 years or older, had newly diagnosed multiple myeloma, had an Eastern Cooperative Oncology Group performance status score of 0-2, and were ineligible for high-dose chemotherapy with autologous stem-cell transplantation because of their age (≥65 years) or comorbidities. Patients were randomly assigned (1:1) using randomly permuted blocks (block size 4) by an interactive web response system to receive 28-day cycles of intravenous daratumumab (16 mg/kg, once per week during cycles 1-2, once every 2 weeks in cycles 3-6, and once every 4 weeks thereafter) plus oral lenalidomide (25 mg on days 1-21 of each cycle) and oral dexamethasone (40 mg on days 1, 8, 15, and 22 of each cycle; daratumumab group) or lenalidomide and dexamethasone alone (control group). Randomisation was stratified by International Staging System disease stage, geographical region, and age. Neither patients nor investigators were masked to treatment assignment. The primary endpoint was progression-free survival, which was centrally assessed, and a secondary endpoint was overall survival (both assessed in the intention-to-treat population). The safety population included patients who received at least one dose of the study treatment. The results presented here are from a prespecified interim analysis for overall survival

Published
2021

23. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

Author

Facon, T. Dimopoulos, M.A. Meuleman, N. Belch, A. Mohty, M. Chen, W.-M. Kim, K. Zamagni, E. Rodriguez-Otero, P. Renwick, W. Rose, C. Tempescul, A. Boyle, E. Manier, S. Attal, M. Moreau, P. Macro, M. Leleu, X. Lorraine Chretien, M. Ludwig, H. Guo, S. Sturniolo, M. Tinel, A. Silvia Monzini, M. Costa, B. Houck, V. Hulin, C. Yves Mary, J.

Abstract

Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment. Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investigated to determine outcomes based on frailty using scores for age, Charlson Comorbidity Index (CCI), and Eastern Cooperative Oncology Group performance status (ECOG PS), instead of the EQ-5D quality-of-life questionnaire, as previously reported. ECOG PS (n = 1618) was investigated in frailty groups: frail (49%) and nonfrail (51%). Frail patients experienced worse progression-free and overall survival vs nonfrail patients. Prognostic assessment was improved when combining frailty and International Staging System stage (I/II vs III). Frail patients had a higher risk of developing grade 3/4 treatment-emergent adverse events. Treatment effects observed in the FIRST trial were confirmed per frailty group and per frailty and ISS group. The use of this ECOG PS–containing frailty scale as a predictive measure of clinical outcomes in patients with transplant-ineligible NDMM is supported by data from the FIRST trial. This score, based on age, CCI, and ECOG PS, can be easily replicated and may help design future myeloma studies in frail or nonfrail elderly patients. © 2019, The Author(s).

Published
2020

26. Treatment of Older Patients with Mantle-Cell Lymphoma

Author

Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., Coiffier, B., Forstpointner, R., Tilly, H., Kanz, L., Feugier, P., Szymczyk, M., Hallek, M., Kremers, S., Lepeu, G., Sanhes, L., Zijlstra, J. M., Bouabdallah, R., Lugtenburg, P. J., Macro, M., Pfreundschuh, M., Procházka, V., Di Raimondo, F., Ribrag, V., Uppenkamp, M., André, M., Klapper, W., Hiddemann, W., Unterhalt, M., and Dreyling, M. H.

Published
2012
Full Text
View/download PDF

33. Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis

Author

Gay, F. Jackson, G. Rosiñol, L. Holstein, S.A. Moreau, P. Spada, S. Davies, F. Lahuerta, J.J. Leleu, X. Bringhen, S. Evangelista, A. Hulin, C. Panzani, U. Cairns, D.A. Di Raimondo, F. Macro, M. Liberati, A.M. Pawlyn, C. Offidani, M. Spencer, A. Hájek, R. Terpos, E. Morgan, G.J. Bladé, J. Sonneveld, P. San-Miguel, J. McCarthy, P.L. Ludwig, H. Boccadoro, M. Mateos, M.-V. Attal, M.

Abstract

Importance: Several trials demonstrated the impact of novel agent-based maintenance in newly diagnosed multiple myeloma (NDMM), but there is no current evidence demonstrating the superiority of one regimen over the other, owing to the lack of direct/indirect comparisons. Objective: To analyze and compare the effectiveness of different maintenance regimens in NDMM via a network meta-analysis. Data Sources: We performed 2 independent searches in PubMed and Cochrane databases, and then we identified all the records registered after 1999 and on or before November 20, 2017. Study Selection: By blinded review, we identified prospective phase 3 randomized trials evaluating novel agent-based maintenance in patients with NDMM; the included studies compared at least 2 maintenance approaches; comparators included placebo and no maintenance. From 364 screened records, 11 studies were included. Data Extraction and Synthesis: We followed (independent extraction) the guidelines provided by the PRISMA Report and the EQUATOR Network. The evidence was synthesized using a network meta-analysis (NMA). To allow comparison of all treatments, no maintenance was selected as common comparator and the effect of placebo was assumed to be the same as no treatment. The best option was identified by a Bayesian consistency model based on hazard ratio (HR), 95% credible interval (CrI), probability of being the best treatment (PbBT), and median ranking distribution (MedR). Main Outcomes and Measures: Outcomes of interest were progression-free survival (PFS) and overall survival (OS). Results: Eleven trials and 8 treatments including a total of 5073 participants were included. By PFS analysis, lenalidomide-based regimens (lenalidomide-prednisone, lenalidomide alone) were identified as the most effective options (HR, 0.39 [95% CrI, 0.28-0.53] and 0.47 [95% CrI, 0.39-0.55], respectively; MedR, 1 and 2; overall PbBT, 74%). Four treatments (thalidomide-interferon, thalidomide-bortezomib, bortezomib-prednisone, thalidomide alone) showed an HR in favor of maintenance. By OS analysis, lenalidomide alone was identified as the best option (HR, 0.76; 95% CrI, 0.51-1.16; MedR, 2; PbBT, 38%), followed by bortezomib-thalidomide and bortezomib-prednisone. Similar features were noticed in the restricted network including transplant trials, in the sensitivity analysis, and in most of the prognostic subgroups. Conclusions and Relevance: Based on PFS and OS results of this NMA, lenalidomide maintenance appears to be the best treatment option, by synthesizing the available evidence of novel agent-based maintenance in the past 20 years. © 2018 American Medical Association. All rights reserved.

Published
2018

34. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY

Author

Cottereau, A., primary, Vercellino, L., additional, Casasnovas, O., additional, Tilly, H., additional, Feugier, P., additional, Fruchart, C., additional, Roulin, L., additional, Oberic, L., additional, Pica, G., additional, Ribrag, V., additional, Abraham, J., additional, Simon, M., additional, Gonzalez, H., additional, Bouabdallah, R., additional, Fitoussi, O., additional, Sebban, C., additional, Lopez, A., additional, Macro, M., additional, Sahnes, L., additional, Morschhauser, F., additional, Trotman, J., additional, Corront, B., additional, Choufi, B., additional, Snauwaert, S., additional, Godmer, P., additional, Copie-Bergman, C., additional, Briere, J., additional, Salles, G., additional, Gaulard, P., additional, Meignan, M., additional, and Thieblemont, C., additional

Published
2019
Full Text
View/download PDF

35. S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS

Author

Moreau, P., primary, Attal, M., additional, Hulin, C., additional, Arnulf, B., additional, Belhadj, K., additional, Benboubker, L., additional, Béné, M. C., additional, Broijl, A., additional, Caillon, H., additional, Caillot, D., additional, Corre, J., additional, Delforge, M., additional, Dejoie, T., additional, Doyen, C., additional, Facon, T., additional, Sonntag, C., additional, Garderet, L., additional, Jie, K.-S., additional, Karlin, L., additional, Kuhnowski, F., additional, Lambert, J., additional, Leleu, X., additional, Lenain, P., additional, Macro, M., additional, Orsini-Piocelle, F., additional, Perrot, A., additional, Stoppa, A.-M., additional, van de Donk, N. W., additional, Wuilleme, S., additional, Zweegman, S., additional, Kolb, B., additional, Touzeau, C., additional, Roussel, M., additional, Tiab, M., additional, Marolleau, J.-P., additional, Meuleman, N., additional, Vekemans, M.-C., additional, Westerman, M., additional, Klein, S. K., additional, Levin, M.-D., additional, Escoffre-Barbe, M., additional, Eveillard, J.-R., additional, Garidi, R., additional, Ahmadi, T., additional, Zhuang, S., additional, Chiu, C., additional, Pei, L., additional, Vanquickelberghe, V., additional, de Boer, C., additional, Smith, E., additional, Deraedt, W., additional, Kampfenkel, T., additional, Schecter, J., additional, Vermeulen, J., additional, Avet-Loiseau, H., additional, and Sonneveld, P., additional

Published
2019
Full Text
View/download PDF

36. PF594 BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Author

Rosiñol, L., primary, Hebraud, B., additional, Oriol, A., additional, Colin, A.-L., additional, Rios, R., additional, Hulin, C., additional, Blanchard, M.J., additional, Caillot, D., additional, Sureda, A., additional, Hernández, M. Teodoro, additional, Arnulf, B., additional, Mateos, M.-V., additional, Macro, M., additional, Miguel, J. San, additional, Belhadj, K., additional, Lahuerta, J.J., additional, Garelik, M.B., additional, Bladé, J., additional, Moreau, P., additional, and Attal, M., additional

Published
2019
Full Text
View/download PDF

37. S874 EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA

Author

Avet-Loiseau, H., primary, Moreau, P., additional, van der Velden, V.H.J., additional, Attal, M., additional, Hulin, C., additional, Arnulf, B., additional, Corre, J., additional, Garderet, L., additional, Karlin, L., additional, Lambert, J., additional, Macro, M., additional, Perrot, A., additional, Sonneveld, P., additional, Levin, M.-D., additional, Klein, S., additional, Chiu, C., additional, Pe, L., additional, Vanquickelberghe, V., additional, de Boer, C., additional, Kampfenkel, T., additional, Vermeulen, J., additional, Wuilleme, S., additional, and Béné, M.C., additional

Published
2019
Full Text
View/download PDF

40. Erratum: Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Author

Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, and Avet-Loiseau, H

Published
2014
Full Text
View/download PDF

43. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial

Author

Hulin, C. Belch, A. Shustik, C. Petrucci, M.T. Dührsen, U. Lu, J. Song, K. Rodon, P. Pégourié, B. Garderet, L. Hunter, H. Azais, I. Eek, R. Gisslinger, H. Macro, M. Dakhil, S. Goncalves, C. Leblanc, R. Romeril, K. Royer, B. Doyen, C. Leleu, X. Offner, F. Leupin, N. Houck, V. Chen, G. Ervin-Haynes, A. Dimopoulos, M.A. Facon, T.

Abstract

Purpose: This analysis of the FIRST trial in patients with newly diagnosed multiple myeloma (MM) ineligible for stem-cell transplantation examined updated outcomes and impact of patient age. Patients and Methods: Patients with untreated symptomatic MM were randomly assigned at a one-to-one-to-one ratio to lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks), stratified by age (≤ 75 v > 75 years), disease stage (International Staging System stage I/II v III), and country. The primary end point was progression-free survival. Rd continuous and MPT were primary comparators. Results: Between August 21, 2008, and March 7, 2011, 1,623 patients were enrolled (Rd continuous, n = 535; Rd18, n = 541; MPT, n = 547), including 567 (35%) age older than 75 years. Higher rates of advanced-stage disease and renal impairment were observed in patients older than 75 versus 75 years of age or younger. Rd continuous reduced the risk of progression or death compared with MPT by 31% (hazard ratio [HR], 0.69; 95% CI, 0.59 to 0.80; P

Published
2016

44. The trade-off between central bank independence and conservatism in a New Keynesian framework

Author

Macro M. Hoeberichts and Sylvester Eijffinger

Subjects
Macroeconomics, Bank rate, Economics and Econometrics, Inflation targeting, media_common.quotation_subject, Monetary policy, Monetary economics, Conservatism, Forward guidance, Interest rate, Political Science and International Relations, New Keynesian economics, Economics, media_common.cataloged_instance, European union, media_common
Abstract

The purpose of this paper is to discuss the issue of Treaty reform and its consequences for monetary policy. Inter alia, the changes include that the institutional set-up will be subtly changed and the European Central Bank (ECB) will be grouped in the first part of the Treaty as one of the “other institutions and advisory bodies”. Possibly more importantly, the euro area as such will be in the position to act legally as itself within the European Union (EU) legal structures. The Eurogroup also will be officially recognized (“Euro-Ecofin-Council”). President Jean-Claude Trichet's concern about the status of the ECB under the new Treaty and fear that by including the bank in a list of EU institutions implies a risk that EU member states could formulate policy recommendations to the ECB, but may also lead to more central bank conservatism with the ECB as explained in our analysis. In this paper we analyze the trade-off between central bank independence and conservatism with New Keynesian framework following Woodford [Woodford, M., 2003. Interest and prices: foundations of a theory of monetary policy. Princeton University Press, Princeton.] and others. Our conclusion is that the trade-off between central bank independence and conservatism still holds within the New Keynesian framework. Politicians should therefore realize that their attempts to downgrade ECB's independence legally and verbally will only increase its conservatism in order to maintain the same inflationary bias and limit the ECB's degrees of freedom with respect to its interest rate policy.

Published
2008
Full Text
View/download PDF

45. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL

Author

Gressin, R., primary, Daguindau, N., additional, Tempescul, A., additional, Moreau, A., additional, Carras, S., additional, Cartron, G., additional, Schmitt, A., additional, Houot, R., additional, Dartigeas, C., additional, Pignon, J., additional, Corm, S., additional, Bannos, A., additional, Mounier, C., additional, Dupuis, J., additional, Macro, M., additional, Fleury, J., additional, Jardin, F., additional, Karlin, L., additional, Damaj, G., additional, Feugier, P., additional, Fornecker, L., additional, Chabrot, C., additional, Ysebaert, I., additional, Callanan, M., additional, and Le Gouill, S., additional

Published
2017
Full Text
View/download PDF

46. Unusual Extramedullary Plasmacytoma: A Rare but Possible Cause of Lymphadenopathy in Chronic Lymphocytic Leukemia

Author

Chantepie, S. P., Cabrera, Q., Mear, J. B., Salaun, V., Lechapt-Zalcman, E., and Macro, M.

Subjects
Article Subject, immune system diseases, hemic and lymphatic diseases, neoplasms
Abstract

Cervical bilateral lymphadenopathy is a frequent event during chronic lymphocytic leukemia (CLL) natural history. However, lymph node biopsy is generally not required as long as transformation into an aggressive lymphoma (Richter syndrome) is not suspected. We present here a rare case of CLL patient who developed progressive bilateral cervical lymph node and bilateral tonsillar hypertrophy. CLL front-line therapy was ineffective leading to adenectomy and diagnosis of concomitant extramedullary plasmacytoma. Radiotherapy did not result in the disappearance of lymphadenopathy. Adenectomy should be performed in CLL cases to avoid misdiagnosis.

Published
2015
Full Text
View/download PDF

47. Modulation of rabbit articular chondrocyte (RAC) proliferation by TGF-β isoforms

Author

Karim Boumediene, Patrick Bogdanowicz, Denis Vivien, Pujol Jp, Macro M, and Lebrun E

Subjects
Cartilage, Articular, Gene isoform, medicine.diagnostic_test, Cell Cycle, DNA replication, Cell Count, Endogeny, Cell Biology, General Medicine, Cell cycle, Biology, Flow Cytometry, Tritium, Molecular biology, Flow cytometry, Paracrine signalling, Transforming Growth Factor beta, medicine, Animals, Rabbits, Beta (finance), Autocrine signalling, Cell Division, Cells, Cultured, Thymidine
Abstract

We have previously shown that TGF-beta 1 exerts a bifunctional effect on RAC proliferation. Added to quiescent cultures, it inhibits the entry of G0/G1 cells into S phase whereas in S phase synchronized populations, it stimulates the DNA replication rate with a delayed G2 + M phase and a subsequent transient increase of cell number. As TGF-beta 2 and beta 3 isoforms are also expressed in bone and cartilage tissues, it was of interest to study their effect on RAC proliferation, in comparison to that of TGF-beta 1. Using cell counting and tritiated thymidine incorporation, we found that all the TGF-beta s used here induced an increase of RAC proliferation rate occurring between 24 and 48 h of exposure. TGF-beta 2 appeared as the most efficient form as judged from the maximum of thymidine labelling. However, TGF-beta 3 induced an increase of cell number slightly higher than both TGF-beta 1 and TGF-beta 2 (+30% versus 20% for TGF-beta 1 and beta 2). TGF-beta 2 and beta 3 were able to stimulate the DNA replication rate as previously demonstrated for TGF-beta 1. However, the effect occurred later for TGF-beta 2 and beta 3 (12 h) than for TGF-beta 1 (6 h). This was confirmed by flow cytometric analysis of DNA content. In addition, immunodetection by flow cytometry demonstrated that all TGF-beta isoforms enhanced endogenous expression of TGF-beta-related peptides. The effect was shown to be associated with the cell cycle S phase and was greater for TGF-beta 3 than for TGF-beta 1 and beta 2. These findings suggest that TGF-beta s could act on RAC functions via autocrine and paracrine ways. Taken together, these data indicate that TGF-beta s may modulate proliferation of articular chondrocytes and therefore could play a role in the activation of these cells in the early stages of osteoarthritis.

Published
1995
Full Text
View/download PDF

48. Continuous Treatment With Lenalidomide and Low-Dose Dexamethasone for Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the First Trial: Impact of Age

Author

Hulin, C., primary, Shustik, C., additional, Belch, A., additional, Petrucci, M.T., additional, Dührsen, U., additional, Lu, J., additional, Song, K., additional, Rodon, P., additional, Garderet, L., additional, Hunter, H., additional, Azais, I., additional, Eek, R., additional, Macro, M., additional, Dakhil, S., additional, Houck, V., additional, Chen, G., additional, Ervin-Haynes, A., additional, Offner, F., additional, Dimopoulos, M.A., additional, and Facon, T., additional

Published
2015
Full Text
View/download PDF

49. Le pomalidomide dans le myélome multiple

Author

Fouquet, G., primary, Macro, M., additional, Decaux, O., additional, Fohrer, C., additional, Guidez, S., additional, Demarquette, H., additional, Le Grand, C., additional, Prodhomme, C., additional, Renaud, L., additional, Bories, C., additional, Herbaux, C., additional, Karlin, L., additional, Roussel, M., additional, Benboubker, L., additional, Hulin, C., additional, Arnulf, B., additional, and Leleu, X., additional

Published
2015
Full Text
View/download PDF

50. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis

Author

Lazareth, A., primary, Song, X.-Y., additional, Coquin, A., additional, Harel, S., additional, Karlin, L., additional, Belhadj, K., additional, Roos-Weil, D., additional, Frenzel, L., additional, Tamburini, J., additional, Macro, M., additional, Chevret, S., additional, Loiseau, H. A., additional, Minvielle, S., additional, Fermand, J. P., additional, Soulier, J., additional, Bories, J. C., additional, and Arnulf, B., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results